All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Meletios A Dimopoulos; Sebastian Grosicki; W Wiktor-Jędrzejczak; Hareth Nahi; Astrid Gruber; Markus Hansson; Neeraj Gupta; Catriona Byrne; Richard Labotka; Zhaoyang Teng; Huyuan Yang; Norbert Grząśko; Shaji Kumar

doi:10.1016/j.ejca.2018.09.011

Related publications

Article2017

An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Meletios A Dimopoulos, Sebastian Grosicki, W Wiktor-Jędrzejczak, Hareth Nahi, Astrid Gruber, Markus Hansson, Catriona Byrne, Richard Labotka, Zhaoyang Teng, Huyuan Yang, Norbert Grząśko, Shaji Kumar

Article2019

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Thierry Façon, Jae Hoon Lee, Philippe Moreau, Rubén Niesvizky, Meletios A Dimopoulos, Roman Hájek, Luděk Pour, Artur Jurczyszyn, Lugui Qiu, Zandra Klippel, Anita Zahlten‐Kumeli, Muhtarjan Osman, Bruno Paiva, Jesús F. San Miguel

Article2023

P-110 Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: final overall survival analysis from the TOURMALINE-MM4 study

Meletios A Dimopoulos, Wee Joo Chng, Shinsuke Iida, María‐Victoria Mateos, Gareth J. Morgan, Sagar Lonial, Ivan Špıčka, Hang Quach, Albert Oriol, Roman Hájek, Mamta Garg, Nicola Giuliani, Meral Beksaç, Eirini Katodritou, Sara Bringhen, Cong Li, Xiaoquan Zhang, Richard Labotka, S. Vincent Rajkumar

Article2018

Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma

Shaji Kumar, Norbert Grząśko, Sosana Delimpasi, W Wiktor-Jędrzejczak, Sebastian Grosicki, Marie‐Christine Kyrtsonis, Andrew Spencer, Neeraj Gupta, Zhaoyang Teng, Catriona Byrne, Richard Labotka, Meletios A Dimopoulos

Article2015

Continuous Treatment With Lenalidomide and Low-Dose Dexamethasone for Patients With Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the First Trial: Impact of Age

Cyrille Hulin, Chaim Shustik, Andrew Belch, Maria Teresa Petrucci, Ulrich Dührsen, Jin Lu, Kevin Song, Philippe Rodon, Laurent Garderet, Hannah Hunter, I Azaïs, Richard Eek, Margaret Macro, Shaker R. Dakhil, Vanessa Houck, G. Chen, Annette Ervin‐Haynes, Fritz Offner, Meletios A Dimopoulos, Thierry Façon